The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes.

Chronic kidney disease Diabetes-related nephropathy Diabetic nephropathy Dipeptidyl peptidase-4 (DPP-4) inhibitors Glucagon-like peptide-1 receptor agonists Type 2 diabetes

Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 28 01 2020
pubmed: 19 3 2020
medline: 19 3 2020
entrez: 19 3 2020
Statut: ppublish

Résumé

This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies.

Identifiants

DOI: 10.1007/s13300-020-00798-x PMID: 32185624 PMC: PMC7136364
pubmed: 32185624
doi: 10.1007/s13300-020-00798-x
pii: 10.1007/s13300-020-00798-x
pmc: PMC7136364
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

835-844

Références

Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–45.
doi: 10.2215/CJN.11491116 pubmed: 5718284
Hole B, et al. UK Renal Registry 19th annual report: chapter 12 multisite dialysis access audit in England, Northern Ireland and Wales in 2015 and 2014 PD one year follow-up: national and centre-specific analyses. Nephron. 2017;137(Suppl 1):269–96.
doi: 10.1159/000481374
Gregg EW, Williams DE, Geiss L. Changes in diabetes-related complications in the United States. N Engl J Med. 2014;371(3):286–7.
Vassalotti JA, Piraino B, Szczech LA. A decade after the KDOQI CKD guidelines: impact on the National Kidney Foundation. Am J Kidney Dis. 2012;60(5):689–91.
doi: 10.1053/j.ajkd.2012.08.013
Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78.
doi: 10.2337/diab.32.2.S64
Retnakaran R, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes. 2006;55(6):1832–9.
doi: 10.2337/db05-1620
Gaede P, et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004;19(11):2784–8.
doi: 10.1093/ndt/gfh470
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–705.
doi: 10.1016/S0140-6736(06)69705-5
Pyke C, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280–90.
doi: 10.1210/en.2013-1934
Schlatter P, et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141(1–3):120–8.
doi: 10.1016/j.regpep.2006.12.016
Muskiet MHA, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605–28.
doi: 10.1038/nrneph.2017.123
Tonneijck L, et al. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am J Physiol Ren Physiol. 2019;316(2):F231–40.
doi: 10.1152/ajprenal.00432.2018
Tonneijck L, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2016;59(7):1412–21.
doi: 10.1007/s00125-016-3938-z pubmed: 4901099
Skov J, et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab. 2016;18(6):581–9.
doi: 10.1111/dom.12651
Zhou X, et al. Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats. Cardiovasc Diabetol. 2015;14:29.
doi: 10.1186/s12933-015-0194-3 pubmed: 4476171
Fujita H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2014;85(3):579–89.
doi: 10.1038/ki.2013.427
Moellmann J, et al. Glucagon-like peptide 1 and its cleavage products are renoprotective in murine diabetic nephropathy. Diabetes. 2018;67(11):2410–9.
doi: 10.2337/db17-1212
FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-developing-drugs-and-therapeuticbiologics-treatment-and-prevention . Accessed 3 Oct 2019.
Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.
doi: 10.1056/NEJMoa1509225 pubmed: 26630143
Muskiet MHA, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859–69.
doi: 10.1016/S2213-8587(18)30268-7
Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
doi: 10.1056/NEJMoa1603827 pubmed: 27295427
Mann JFE, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48.
doi: 10.1056/NEJMoa1616011
Davies MJ, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222–30.
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
doi: 10.1056/NEJMoa1607141
Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–399.
doi: 10.1056/NEJMoa1612917
Bethel MA, et al. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial. Diabetes Care. 2020;43(2):446–52.
doi: 10.2337/dc19-1065
Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.
doi: 10.1016/S0140-6736(18)32261-X pubmed: 30291013
Tuttle KR, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605–17.
doi: 10.1016/S2213-8587(18)30104-9
Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
doi: 10.1016/S0140-6736(19)31149-3
Gerstein HC, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–8.
doi: 10.1016/S0140-6736(19)31150-X
Dubois-Laforgue D, et al. Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists. Diabetes Res Clin Pract. 2014;103(3):e53–5.
doi: 10.1016/j.diabres.2013.11.014
Gariani K, de Seigneux S, Moll S. Acute interstitial nephritis after treatment with liraglutide. Am J Kidney Dis. 2014;63(2):347.
doi: 10.1053/j.ajkd.2013.10.057
Chen YT, et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med. 2013;11:270.
doi: 10.1186/1479-5876-11-270 pubmed: 4231365
Gutzwiller JP, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89(6):3055–61.
doi: 10.1210/jc.2003-031403
Sharma T, Paixao R, Villabona C. GLP-1 agonist associated acute kidney injury: a case report and review. Diabetes Metab. 2019;45(5):489–91.
doi: 10.1016/j.diabet.2017.12.002
Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.
doi: 10.1016/S2213-8587(19)30249-9 pubmed: 31422062
A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). 2019. https://clinicaltrials.gov/ct2/show/NCT03819153 . Accessed 23 Oct 2019.
Perkovic V, et al. Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME(R) trial. Nephrol Dial Transplant. 2019. https://doi.org/10.1093/ndt/gfz179 .
doi: 10.1093/ndt/gfz179

Auteurs

Win L Yin (WL)

Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK.

Steve C Bain (SC)

Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK.
Diabetes Research Group, Swansea University Medical School, Swansea, SA2 8PP, UK.

Thinzar Min (T)

Diabetes Research Group, Swansea University Medical School, Swansea, SA2 8PP, UK. thinzar.min@swansea.ac.uk.
Department of Diabetes and Endocrinology, Neath Port Talbot Hospital, Swansea Bay University Health Board, Swansea, SA12 7BX, UK. thinzar.min@swansea.ac.uk.

Classifications MeSH